Galmed Pharmaceuticals Financials - Benzinga

Galmed Pharmaceuticals Ltd

GLMDNASDAQ

Trade with Public

Trade with Public

$4.17

-0.14-3.27%

At close: Aug 28, 5:00 PM EST

$4.30

0.133.24%

After Hours: 4:58 PM EST

Overview News Earnings Forecast Price TargetsFinancialsSentiment Compare Stock Report

Galmed Pharmaceuticals Financials

Galmed Pharmaceuticals (GLMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share

Benzinga Newsdesk

PRO
Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share

Benzinga Newsdesk

PRO
Galmed Pharmaceuticals Q1 EPS $(0.62) Beats $(0.89) Estimate

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.89) by 30.34 percent. This is a 70.48 percent increase over losses of $(2.10) per share

Benzinga Newsdesk

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

Avi Kapoor

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings

Avi Kapoor

Gold Edges Lower; US Homebuilder Sentiment Rises For September

Avi Kapoor